Silence Therapeutics to Present at Jefferies London Healthcare Conference
Silence Therapeutics to Present at Jefferies London Healthcare Conference
Silence Therapeutics to Present at Jefferies London Healthcare Conference
沉默治療公司將在傑富瑞倫敦醫療會議上亮相
11 November 2021
2021年11月11日
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies London Healthcare Conference being held November 16-18, 2021.
The on-demand presentation will be available beginning on Thursday, November 18 at 8:00am GMT / 3:00am ET and can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company's website following the conference.
亞洲網倫敦和倫敦寂靜治療公司今天宣佈，該公司將出席於2021年11月16日至18日舉行的傑弗瑞倫敦醫療會議(Jefferies London Healthcare Conference)。該公司是發現、開發和交付新型短幹擾核糖核酸(SiRNA)療法的領先企業，該療法用於治療有重大醫療需求的疾病，並將於2021年11月16日至18日在傑弗瑞倫敦醫療保健大會上亮相，該公司今天宣佈，該公司將出席2021年11月16日至18日舉行的傑弗瑞倫敦醫療保健大會(Jefferies London Healthcare Conference)。點播演示文稿將於11月18日(星期四)格林尼治標準時間上午8：00/美國東部時間凌晨3：00開始提供，並可通過Silence網站的投資者部分訪問，網址為www.Silent-Treateutics.com。會議結束後，公司網站將提供網絡直播的存檔重播。
Enquiries:
查詢：
|
Silence Therapeutics plc Gem Hopkins, Head of IR and Corporate Communications ir@silence-therapeutics.com |
Tel: +1 (646) 637-3208 |
| Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence |
Tel: +44 (0) 20 7597 5970 |
|
European PR Consilium Strategic Communications Mary-Jane Elliott/ Angela Gray / Chris Welsh silencetherapeutics@consilium-comms.com |
Tel: +44 (0) 20 3709 5700 |
|
沉默治療公司 吉姆·霍普金斯(Gem Hopkins)，投資者關係和企業公關主管 電子郵箱：ir@Silence-Treateutics.com |
電話：+1(646)637-3208 |
| 天達銀行(Investec Bank Plc) (指定顧問及經紀) 丹尼爾·亞當斯/加里·克拉倫斯 |
電話：+44(0)207597570 |
|
歐洲人PR Consilium戰略傳播 瑪麗-簡·埃利奧特/安吉拉·格雷/克里斯·威爾士 郵箱：silenceTreateutics@conconlium-comms.com |
電話：+44(0)2037095700 |
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron-loading anemia conditions. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.
關於沉默療法沉默治療公司正在開發新一代藥物，方法是利用人體自然的RNA幹擾(RNAi)機制，抑制特定靶基因的表達，這些基因被認為在有重大未得到滿足的需求的疾病的病理中發揮作用。Silent公司專有的mRNAi金™平臺可以用來創建siRNA(短幹擾RNA)，它可以精確地針對肝臟中的疾病相關基因並使其沉默，這代表着一個巨大的機會。SILE公司全資擁有的候選產品包括SLN360和SLN124。SLN360旨在滿足在降低天生高水平脂蛋白(A)人羣心血管風險方面的高和普遍的未得到滿足的醫療需求，SLN124旨在解決鐵負荷貧血癥問題。沉默公司還與阿斯利康公司、美林製藥公司和漢索製藥公司等公司保持着持續的研發合作。欲瞭解更多信息，請訪問網址：https://www.silence-therapeutics.com/.。
譯文內容由第三人軟體翻譯。